Literature DB >> 12107240

Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.

Tzu-Hao Wang1, Shang-Gwo Horng, Chia-Lin Chang, Hsien-Ming Wu, Yi-Ju Tsai, Hsin-Shih Wang, Yung-Kuei Soong.   

Abstract

Ovarian hyperstimulation syndrome (OHSS), a life-threatening complication occurring in stimulated ovarian cycles, arises from treatment with gonadotropin for induction of follicular maturation in infertile women. Clinical characteristics of OHSS include ascites and pleural effusion induced by increased vascular permeability, where vascular endothelial growth factor (VEGF) was suspected to be the culprit. To test whether the effects of human CG (hCG) on the pathogenesis of OHSS were mediated through the VEGF produced by luteinized granulosa cells, we measured estradiol, VEGF, IGF-II levels in serum, and follicular fluid and analyzed their mRNA expression in luteinized granulosa cells obtained from 101 women (58 with OHSS and 43 controls) who underwent in vitro fertilization and embryo transfer. This study presents the first evidence that hCG up-regulated VEGF expression of granulosa cells in the OHSS, not the control groups, and that follicular VEGF worked through an autocrine mechanism using its kinase insert domain-containing receptor, not the fms-like tyrosine kinase receptor. We calculated total follicular production of VEGF, by multiplying follicular concentrations by follicular volumes, and verified that an increase in total follicular production of VEGF accounted for elevated serum levels of VEGF, which was associated with the development of OHSS. These findings demonstrate that through up-regulation of VEGF, hCG plays a significant role in the pathogenesis of OHSS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107240     DOI: 10.1210/jcem.87.7.8651

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

Review 2.  Ovarian hyperstimulation syndrome: pathophysiology and prevention.

Authors:  Carolina O Nastri; Rui A Ferriani; Isa A Rocha; Wellington P Martins
Journal:  J Assist Reprod Genet       Date:  2010-02-06       Impact factor: 3.412

3.  THE ROLE OF HIGH FOLLICULAR LEVELS OF ANGIOTENSIN II AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN ANTICIPATING THE DEVELOPMENT OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN PATIENTS WITH PROPHYLACTIC CABERGOLINE THERAPY UNDERGOING AN IN VITRO FERTILIZATION PROCEDURE.

Authors:  M Surcel; M Surcel; C Zlatescu-Marton; R Micu; G I Nemeti; D D Axente; C Mirza; I Neamtiu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

4.  The regulators of VEGF expression in mouse ovaries.

Authors:  So Young Shin; Ho-Jung Lee; Duck-Sung Ko; Hoi-Chang Lee; Won Il Park
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

5.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

Review 6.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

7.  Human chorionic gonadotrophin beta expression in malignant Barrett's oesophagus.

Authors:  Anne Couvelard; François Paraf; Dominique Vidaud; Sylvie Dubois; Michel Vidaud; Jean-François Fléjou; Claude Degott
Journal:  Virchows Arch       Date:  2004-08-10       Impact factor: 4.064

Review 8.  VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.

Authors:  Nikita Naredi; Pankaj Talwar; K Sandeep
Journal:  Med J Armed Forces India       Date:  2012-09-11

9.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

10.  Continuous follicle-stimulating hormone exposure from pituitary adenoma causes periodic follicle recruitment and atresia, which mimics ovarian hyperstimulation syndrome.

Authors:  Mika Kanaya; Tsuyoshi Baba; Yoshimitsu Kitajima; Keiko Ikeda; Ayumi Shimizu; Miyuki Morishita; Hiroyuki Honnma; Toshiaki Endo; Tsuyoshi Saito
Journal:  Int J Womens Health       Date:  2012-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.